BRIEF—Pharmacosmos and partner launch MonoVer in Japan

Danish drugmaker Pharmacosmos has announced the launch of its intravenous iron deficiency anemia medicine MonoVer (ferric derisomaltose) in Japan.

The launch follows a successful bid for reimbursement by the firm’s strategic partner Nippon Shinyaku, which will undertake commercialization in the country.

Chief executive Tobias Christensen said: “The launch in Japan marks a milestone for Pharmacosmos, since we are now represented with ferric derisomaltose in the three largest global pharma markets.”

He added: “Our product fits with the needs of Japanese patients and hospitals, and the strength of our partner Nippon Shinyaku makes us see this opportunity as very promising for Pharmacosmos.”